tetano
Editor, Senior Moderator
Clin Kidney J
. 2022 Apr 9;15(8):1562-1573.
doi: 10.1093/ckj/sfac093. eCollection 2022 Aug.
Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination
Nayara Panizo[SUP] 1 [/SUP], Eliseo Albert[SUP] 2 [/SUP], Elena Giménez-Civera[SUP] 1 [/SUP], Maria Jesús Puchades[SUP] 1 [/SUP], Luis D'Marco[SUP] 3 [/SUP], Lorena Gandía-Salmerón[SUP] 1 [/SUP], Estela Giménez[SUP] 2 [/SUP], Ignacio Torre[SUP] 2 [/SUP], Asunción Sancho[SUP] 4 [/SUP], Eva Gavela[SUP] 4 [/SUP], Miguel Gonzalez-Rico[SUP] 1 [/SUP], Marco Montomoli[SUP] 1 [/SUP], Carmen Maria Perez-Baylach[SUP] 5 [/SUP], Begoña Bonilla[SUP] 5 [/SUP], Camila Solano[SUP] 1 [/SUP], Mª Fernanda Alvarado[SUP] 1 [/SUP], Isidro Torregrosa[SUP] 1 [/SUP], María Jesús Alcaraz[SUP] 2 [/SUP], José Luis Górriz[SUP] 1 [/SUP], David Navarro[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Little is known regarding the dynamics of antibody and T-cell responses in chronic kidney disease (CKD) following coronavirus disease 2019 (COVID-19) vaccination.
Methods: Prospective observational cohort study including 144 participants on haemodialysis (HD) (n = 52) or peritoneal dialysis (PD) (n = 14), those undergoing kidney transplantation (KT) (n = 30) or those with advanced CKD (ACKD) not on dialysis and healthy controls (n = 18). Anti-Spike (S) antibody and T-cell responses were assessed at 15 days (15D) and 3 months (3M) after complete vaccination schedule. HD, PD and KT patients received mRNA vaccines (mRNA-123 and BNT162b2). Most ACKD patients received BNT162b2 (n = 23), or Ad26.COV.2.S (4). Most controls received BNT162b2 (n = 12), or Ad26.COV.2.S (n = 5).
Results: Anti-S antibodies at 15D and 3M were detectable in 95% (48/50)/98% (49/50) of HD patients, 93% (13/14)/100% of PD patients, 67% (17/26)/75% (21/28) of KT patients and 96% (25/26)/100% (24/24) of ACKD patients. Rates for healthy controls were 81% (13/16)/100% (17/17). Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2-S) infection was documented in four (7.7%) HD patients, two (14.3%) PD patients, two (6.7%) KT patients, one (5.55%) healthy control and in no ACKD patient. Antibody levels decreased at 3M in HD (P = .04), PD (P = .008) and ACKD patients (P = .0009). In KT patients, levels increased (P = .04) between 15D and 3M, although they were low at both time points.T-cell responses were detected in HD patients in 37 (80%) at baseline, 35 (70%) at 15D and 41 (91%) at 3M. In PD patients, T-cell responses appeared in 8 (67%) at baseline, 13 (93%) at 15D and 9 (100%) at 3M. In KT patients, T-cell responses were detected in 12 (41%) at baseline, 22 (84%) at 15D and 25 (96%) at 3M. In ACKD patients, T-cell responses were detected in 13 (46%) at baseline, 20 (80%) at 15D and 17 (89%) at 3M. None of healthy controls showed T-cell response at baseline, 10 (67%) at 15D and 8 (89%) at 3M.
Conclusions: Most HD, PD and ACKD patients develop SARS-CoV-2-S antibody responses comparable to that of healthy controls, in contrast to KT recipients. Antibody waning at 3M was faster in HD, PD and ACKD patients. No differences in SARS-CoV-2 T-cell immunity responses were noticed across study groups.
Keywords: SARS-CoV-2-S T-cells; SARS-CoV-2-S antibodies; chronic kidney disease; dialysis; kidney transplantation.
. 2022 Apr 9;15(8):1562-1573.
doi: 10.1093/ckj/sfac093. eCollection 2022 Aug.
Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination
Nayara Panizo[SUP] 1 [/SUP], Eliseo Albert[SUP] 2 [/SUP], Elena Giménez-Civera[SUP] 1 [/SUP], Maria Jesús Puchades[SUP] 1 [/SUP], Luis D'Marco[SUP] 3 [/SUP], Lorena Gandía-Salmerón[SUP] 1 [/SUP], Estela Giménez[SUP] 2 [/SUP], Ignacio Torre[SUP] 2 [/SUP], Asunción Sancho[SUP] 4 [/SUP], Eva Gavela[SUP] 4 [/SUP], Miguel Gonzalez-Rico[SUP] 1 [/SUP], Marco Montomoli[SUP] 1 [/SUP], Carmen Maria Perez-Baylach[SUP] 5 [/SUP], Begoña Bonilla[SUP] 5 [/SUP], Camila Solano[SUP] 1 [/SUP], Mª Fernanda Alvarado[SUP] 1 [/SUP], Isidro Torregrosa[SUP] 1 [/SUP], María Jesús Alcaraz[SUP] 2 [/SUP], José Luis Górriz[SUP] 1 [/SUP], David Navarro[SUP] 2 [/SUP]
Affiliations
- PMID: 35880064
- PMCID: PMC9047236
- DOI: 10.1093/ckj/sfac093
Abstract
Background: Little is known regarding the dynamics of antibody and T-cell responses in chronic kidney disease (CKD) following coronavirus disease 2019 (COVID-19) vaccination.
Methods: Prospective observational cohort study including 144 participants on haemodialysis (HD) (n = 52) or peritoneal dialysis (PD) (n = 14), those undergoing kidney transplantation (KT) (n = 30) or those with advanced CKD (ACKD) not on dialysis and healthy controls (n = 18). Anti-Spike (S) antibody and T-cell responses were assessed at 15 days (15D) and 3 months (3M) after complete vaccination schedule. HD, PD and KT patients received mRNA vaccines (mRNA-123 and BNT162b2). Most ACKD patients received BNT162b2 (n = 23), or Ad26.COV.2.S (4). Most controls received BNT162b2 (n = 12), or Ad26.COV.2.S (n = 5).
Results: Anti-S antibodies at 15D and 3M were detectable in 95% (48/50)/98% (49/50) of HD patients, 93% (13/14)/100% of PD patients, 67% (17/26)/75% (21/28) of KT patients and 96% (25/26)/100% (24/24) of ACKD patients. Rates for healthy controls were 81% (13/16)/100% (17/17). Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2-S) infection was documented in four (7.7%) HD patients, two (14.3%) PD patients, two (6.7%) KT patients, one (5.55%) healthy control and in no ACKD patient. Antibody levels decreased at 3M in HD (P = .04), PD (P = .008) and ACKD patients (P = .0009). In KT patients, levels increased (P = .04) between 15D and 3M, although they were low at both time points.T-cell responses were detected in HD patients in 37 (80%) at baseline, 35 (70%) at 15D and 41 (91%) at 3M. In PD patients, T-cell responses appeared in 8 (67%) at baseline, 13 (93%) at 15D and 9 (100%) at 3M. In KT patients, T-cell responses were detected in 12 (41%) at baseline, 22 (84%) at 15D and 25 (96%) at 3M. In ACKD patients, T-cell responses were detected in 13 (46%) at baseline, 20 (80%) at 15D and 17 (89%) at 3M. None of healthy controls showed T-cell response at baseline, 10 (67%) at 15D and 8 (89%) at 3M.
Conclusions: Most HD, PD and ACKD patients develop SARS-CoV-2-S antibody responses comparable to that of healthy controls, in contrast to KT recipients. Antibody waning at 3M was faster in HD, PD and ACKD patients. No differences in SARS-CoV-2 T-cell immunity responses were noticed across study groups.
Keywords: SARS-CoV-2-S T-cells; SARS-CoV-2-S antibodies; chronic kidney disease; dialysis; kidney transplantation.